Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Specimen Handling 280Magnetic Resonance Spectroscopy 233pembrolizumab 220Carboplatin 180Cisplatin 146Biopsy 146Cyclophosphamide 138Paclitaxel 128Nivolumab 118Bevacizumab 106Gemcitabine 105Radiotherapy 90Dexamethasone 83Pemetrexed 79fludarabine 74Docetaxel 74atezolizumab 73Fluorouracil 73Doxorubicin 73Radiation 72Leucovorin 68Rituximab 66Oxaliplatin 64venetoclax 60Prednisone 60durvalumab 58Cetuximab 56Vincristine 55Etoposide 54Lenalidomide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
JNJ-64264681 × 30 days × Clear all
NCT06788509 2026-06-05

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Janssen Research & Development, LLC

Phase 1 Enrolling by invitation
120 enrolled
GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡